PCM
FLGT icon

Portolan Capital Management’s Fulgent Genetics FLGT Stock Holding History

Portolan Capital Management’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-106,642
Closed -$1.7M – 159
2026
Q1 		$1.7M Sell
106,642
-62,948
-37% -$1.37M 0.09% 127
2025
Q4 		$4.46M Buy
+169,590
New +$4.4M 0.24% 111

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Portolan Capital Management's FLGT Position: Q2 2026 in Review

Portolan Capital Management sold out of Fulgent Genetics (FLGT) in Q2 2026, closing a stake of 106,642 shares — an estimated $1.7M sold.

Portolan Capital Management first reported a position in FLGT in Q4 2025 and held it in 2 quarters. The position peaked at $4.46M in Q4 2025. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Portolan Capital Management reported no remaining Fulgent Genetics position as of Q2 2026 after selling out during the quarter.
  • Portolan Capital Management sold 106,642 Fulgent Genetics shares in Q2 2026, an estimated $1.7M.
  • Portolan Capital Management first reported a position in Fulgent Genetics in Q4 2025 and held it in 2 quarters.
  • Portolan Capital Management's Fulgent Genetics position peaked at $4.46M in Q4 2025.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Portolan Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.